Search
Artemisia vulgaris root
go.drugbank.com/drugs/DB14170ApprovedArtemisia vulgaris root allergenic extract is used in allergenic testing.
Mixtures: Toe Corrector CompositeOctyl triazone
go.drugbank.com/drugs/DB15469InvestigationalMixtures: The Classeum Co., Ltd., BRING GREEN Tea Tree CICA Cooling SunCategories: Heterocyclic Compounds, 1-RingBexarotene
go.drugbank.com/drugs/DB00307ApprovedInvestigationalBexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersSynonyms: 4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid, 4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acidDurvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigational[L12624] It is additionally approved in Canada under the same name (Imfinzi) for similar indications, as well as the treatment of patients with locally advanced or metastatic urothelial carcinoma. … [L12621,L12627] Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous injections.
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: IMFINZI® 50 MG/ML CONCENTRADO PARA SOLUCIÓN PARA INFUSIÓN, IMFINZI 120 MG/2.4 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADETTovorafenib
go.drugbank.com/drugs/DB15266ApprovedInvestigational[A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. … Tovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersSynonyms: 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-, 6-Amino-5-chloro-N-((1R)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl)-4-pyrimidinecarboxamideFlumazenil
go.drugbank.com/drugs/DB01205ApprovedInvestigationalFumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine … receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system.
Categories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household settingProducts: ANESED-R 1 MG/10 ML IV ENJEKSİYONLUK ÇÖZELTİ, 5 ADET, ANESED-R 0.5 MG/5 ML IV ENJEKSİYONLUK ÇÖZELTİ, 5 ADETRaxibacumab
go.drugbank.com/drugs/DB08902ApprovedInvestigationalRaxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. … Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.
Quercus alba pollen
go.drugbank.com/drugs/DB10376ApprovedQuercus alba pollen, or oak white pollen, is a non-standardized allergen extract used for the diagnosis and treatment of allergic disease to grass pollen. … Diagnostic allergenic extracts are primarily indicated for establishing clinical relevance of specific allergens to which the patient has been exposed and the degree of sensitivity the patient has toward
Mixtures: 9 Tree Mix, 9 Tree MixOdevixibat
go.drugbank.com/drugs/DB16261ApprovedInvestigational[A236808,L34793] Odevixibat is the first approved non-surgical treatment option for PFIC.[L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid]. … Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 2-RingTetrachlorodecaoxide
go.drugbank.com/drugs/DB05389ApprovedThe Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the … The trial is being conducted in Germany at the University of Heidelberg and the National Centre for Tumor Diseases.
Categories: Compounds used in a research, industrial, or household setting